Active-ingredient Dossier

Rituximab

Active-ingredient Dossier for Rituximab (monoclonal antibody). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.

Brand: RIXIMYO
Brand: RUXIENCE
Brand: TRUXIMA
Therapeutic area: Immunology
Therapeutic area: Oncology

What is Rituximab Rituximab is a monoclonal antibody .

Australian brands containing

Rituximab — RIXIMYO — RUXIENCE — TRUXIMA

Therapeutic areas

Rituximab is registered in oncology, with three brands available in this therapeutic area .

Sponsor landscape

Rituximab is marketed by three sponsors: Sandoz, Pfizer, and Celltrion Healthcare .

PBS and regulatory activity

Three brands containing rituximab have PBS-listed items, with the latest PBS schedule date of 1 May 2026 . In the 2020–21 fiscal year, rituximab products generated government expenditure of $66,431,843.61 across 40,250 prescriptions . Three brands have PBAC outcomes on record, with the latest PBAC outcome dated 1 March 2022 .